{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:11:25Z","timestamp":1770909085440,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,4]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>In the last few years, treatment of head and neck squamous cell carcinoma (HNSCC) has been enhanced by the emergence of immunotherapy. A biological phenomenon unique to immunotherapy is pseudoprogression, an increase in tumor burden or the appearance of a new lesion subsequently followed by tumor regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 78-year-old man complaining of a lump (6*4\u2009cm) gradually swelling on the right side of his neck with recurrent buccal mucosa squamous cell carcinoma presented to our institution. Two months prior, he received resection of the buccal lesion but refused suggested adjuvant chemoradiotherapy after the operation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Recurrent buccal mucosa squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Induction immunotherapy was initiated, followed by a new node appearing on the surface of the neck mass. We considered the presence of pseudoprogression and continued with immunotherapy. The patient received immunotherapy combined with chemotherapy and intensity-modulated radiation therapy (IMRT) consecutively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient experienced an excellent recovery with the disappearance of pain and the lump, along with return of a healthy appetite, weight gain and positive outlook. Complete response (CR) was also noted by magnetic resonance imaging (MRI) scan, with the upper right neck mass significantly retreated to unclear display. The patient is still alive with stable, asymptomatic disease at the time of this writing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>These results provide confidence in the safety and efficacy of radical chemo-radio-immunotherapy for the treatment of recurrent, unresectable or metastatic HNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000033797","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T02:05:26Z","timestamp":1691287526000},"page":"e33797","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report"],"prefix":"10.1097","volume":"102","author":[{"given":"Jiawei","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Health Care, Jinling Hospital, Medical School of Nanjing University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayong","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feijiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-1002","authenticated-orcid":false,"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma.","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260212","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/jim-2018-000743","article-title":"Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives.","volume":"66","author":"Samra","year":"2018","journal-title":"J Investig Med"},{"key":"R3-20260212","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R4-20260212","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.oraloncology.2016.10.007","article-title":"Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.","volume":"62","author":"Baxi","year":"2016","journal-title":"Oral Oncol"},{"key":"R5-20260212","article-title":"Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer.","volume":"13:1959","author":"Semrau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R6-20260212","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.21037\/apm-20-1485","article-title":"Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report.","volume":"10","author":"Wu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"R7-20260212","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R8-20260212","first-page":"16","article-title":"Re-irradiation for oligoprogression under nivolumab in recurrent head and neck squamous cell carcinoma: a case report.","volume":"23","author":"Bonomo","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"R9-20260212","doi-asserted-by":"crossref","first-page":"402","DOI":"10.21037\/atm.2020.02.96","article-title":"Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report.","volume":"8","author":"Tang","year":"2020","journal-title":"Ann Transl Med"},{"key":"R10-20260212","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors.","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"R11-20260212","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R12-20260212","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025.","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"R13-20260212","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy.","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"R14-20260212","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pin.12714","article-title":"A case of metastatic renal clear cell carcinoma treated with nivolumab.","volume":"68","author":"Tabei","year":"2018","journal-title":"Pathol Int"},{"key":"R15-20260212","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab.","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:08:05Z","timestamp":1770905285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":15,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033797","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,4]]}}}